{"id":"W4379335619","doi":"10.1200/jco.2023.41.16_suppl.5500","title":"KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Chemotherapy; Cervical cancer; Placebo; Internal medicine; Oncology; Interim analysis; Gemcitabine; Cancer; Cisplatin; Surgery; Randomized controlled trial; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004885364,0.002155795,0.002562956,0.0004738401,0.0005636385,0.001228915,0.001281562,0.002019908,0.0103016],"category_scores_gemma":[0.002707032,0.0007715968,0.002677792,0.0004979919,0.001045579,0.00127522,0.0007018717,0.003297336,0.001539558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000972721,"about_ca_system_score_gemma":0.001824407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000584042,"about_ca_topic_score_gemma":0.001881094,"domain_scores_codex":[0.9986019,0.0008155625,0.0000905872,0.0002238252,0.00009844878,0.0001696742],"domain_scores_gemma":[0.9985096,0.0003150917,0.0004905444,0.0001611699,0.0001132571,0.0004103582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9784177,0.005713815,0.0004702122,0.000460281,0.0009578385,0.00001984885,0.00002755551,0.0003280961,0.004883038,0.00006583491,0.001122989,0.007532808],"study_design_scores_gemma":[0.88288,0.1102267,0.003142528,0.00003596619,0.001241365,0.00004088171,0.00001624657,0.0002287674,0.001088545,0.0001164667,0.000962929,0.00001948012],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9669648,0.004357021,0.001672955,0.0006717645,0.0004656398,0.01212597,0.008632108,0.0003302002,0.004779558],"genre_scores_gemma":[0.9687122,0.00198853,0.003392225,0.001430144,0.0004052797,0.01168877,0.007413496,0.00008012025,0.004889126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0103016,"threshold_uncertainty_score":0.03446227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.305002818616517,"score_gpt":0.5088345386815675,"score_spread":0.2038317200650505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}